Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WA | N.MMED.WR | N.MMED.WS | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Post by josameyeron Oct 23, 2010 9:55am
504 Views
Post# 17602528

Reflection on Gross proceeds.

Reflection on Gross proceeds.Offering on gross proceeds stated to be $57 500 000 Canadian.Over allotment option exercised.Appoximately 21 million used within one day of closing to reduce the debt. in US dollars. A further 21 million to be applied to the unwinding of the hedge in US dollars A further 5 milion Canadian to be applied to the working capital . That indicates a total of 42 mill US, add 3% for the exchange  I believe is 126000 dollars add the 5 million Canadian,  that was to go to operations gives us a total of $47 012 600 for expenditures.Take the given $57 500 000 than deduct the$47 012 600 and that leaves $10 487 400 dollars.My question is ,take away expenses, what happens to the balance.? Was the over allotment not accounted for? Or am I missing something If I am in eror I stand corrected. Some opinions please.Please DYODD. Cheers to all..Josa
Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse